Review Article Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia

The Ikaros transcription factor is crucial for many aspects of hematopoiesis. Loss of function mutations in IKZF1, the gene encoding Ikaros, have been implicated in adult and pediatric B cell acute lymphoblastic leukemia (B-ALL). These mutations result in haploinsufficiency of the Ikaros gene in approximately half of the cases. The remaining cases contain more severe or compound mutations that lead to the generation of dominant-negative proteins or complete loss of function. All IKZF1 mutations are associated with a poor prognosis. Here we review the current genetic, clinical and mechanistic evidence for the role of Ikaros as a tumor suppressor in B-ALL.

[1]  Julia C. Engelmann,et al.  Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia , 2013, Leukemia.

[2]  B. Drénou,et al.  Biclonal and biallelic deletions occur in 20% of B-ALL cases with IKZF1 mutations , 2013, Leukemia.

[3]  Ryan D. Morin,et al.  Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. , 2012, Cancer cell.

[4]  R. Foà,et al.  IKAROS Deletions Dictate a Unique Gene Expression Signature in Patients with Adult B-Cell Acute Lymphoblastic Leukemia , 2012, PloS one.

[5]  M. Loh,et al.  Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. , 2012, Blood.

[6]  Markus Werner,et al.  FoxO1 induces Ikaros splicing to promote immunoglobulin gene recombination , 2012, The Journal of experimental medicine.

[7]  S. Shen,et al.  Newly diagnosed acute lymphoblastic leukemia in China (II): prognosis related to genetic abnormalities in a series of 1091 cases , 2012, Leukemia.

[8]  Kiran C. Bobba,et al.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.

[9]  J. V. van Dongen,et al.  Highly sensitive MRD tests for ALL based on the IKZF1 Δ3–6 microdeletion , 2011, Leukemia.

[10]  C. Mullighan.  Genomic profiling of B-progenitor acute lymphoblastic leukemia. , 2011, Best practice & research. Clinical haematology.

[11]  M. Greaves,et al.  Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia. , 2011, Blood.

[12]  R. Houlston,et al.  Role of 657del5 NBN mutation and 7p12.2 (IKZF1), 9p21 (CDKN2A), 10q21.2 (ARID5B) and 14q11.2 (CEBPE) variation and risk of childhood ALL in the Polish population. , 2011, Leukemia research.

[13]  Hsuan-Yu Chen,et al.  IKZF1 deletions predict a poor prognosis in children with B‐cell progenitor acute lymphoblastic leukemia: A multicenter analysis in Taiwan , 2011, Cancer science.

[14]  P. Kastner,et al.  Role of Ikaros in T-cell acute lymphoblastic leukemia. , 2011, World journal of biological chemistry.

[15]  F. Sigaux,et al.  Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse , 2011 .

[16]  A. Kohlmann,et al.  A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases , 2011, Leukemia.

[17]  C. Harrison,et al.  Evaluation of multiplex ligation‐dependent probe amplification as a method for the detection of copy number abnormalities in B‐cell precursor acute lymphoblastic leukemia , 2010, Genes, chromosomes & cancer.

[18]  B. Meissner,et al.  IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol , 2010, Haematologica.

[19]  C. V. D. Schoot,et al.  Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia , 2011, Leukemia.

[20]  A. Veerman,et al.  IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL , 2010, Leukemia.

[21]  J. Downing,et al.  Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. , 2010, Blood.

[22]  M. Mandal,et al.  Ikaros and Aiolos Inhibit Pre-B-Cell Proliferation by Directly Suppressing c-Myc Expression , 2010, Molecular and Cellular Biology.

[23]  B. Johansson,et al.  Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations , 2010, Leukemia.

[24]  F. Sigaux,et al.  Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia , 2010, Leukemia.

[25]  M. Busslinger,et al.  STAT5 in B cell development and leukemia. , 2010, Current opinion in immunology.

[26]  F. Sigaux,et al.  Genetic inactivation of Ikaros is a rare event in human T-ALL. , 2010, Leukemia research.

[27]  E. Papaemmanuil,et al.  Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. , 2010, Blood.

[28]  M. Apostolova,et al.  Deletions of Immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia , 2010, BMC Genomics.

[29]  R. Foà,et al.  IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R. Foà,et al.  Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). , 2009, Blood.

[31]  Ching-Hon Pui,et al.  Germline genomic variants associated with childhood acute lymphoblastic leukemia , 2009, Nature Genetics.

[32]  E. Papaemmanuil,et al.  Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia , 2009, Nature Genetics.

[33]  N. Heisterkamp,et al.  Pre–B cell receptor–mediated cell cycle arrest in Philadelphia chromosome–positive acute lymphoblastic leukemia requires IKAROS function , 2009, The Journal of experimental medicine.

[34]  P. Kastner,et al.  Ikaros controls isotype selection during immunoglobulin class switch recombination , 2009, The Journal of experimental medicine.

[35]  Jiangwen Zhang,et al.  Genome-wide lineage-specific transcriptional networks underscore Ikaros-dependent lymphoid priming in hematopoietic stem cells. , 2009, Immunity.

[36]  W. Evans,et al.  A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.

[37]  Christopher B. Miller,et al.  Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. , 2009, The New England journal of medicine.

[38]  James R. Downing,et al.  Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia , 2008, Science.

[39]  R. Foà,et al.  Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. , 2008, Blood.

[40]  P. Kastner,et al.  Ikaros Represses the Transcriptional Response to Notch Signaling in T-Cell Development , 2008, Molecular and Cellular Biology.

[41]  Ignacio A. Demarco,et al.  Regulation of B cell fate commitment and immunoglobulin heavy-chain gene rearrangements by Ikaros , 2008, Nature Immunology.

[42]  Christopher B. Miller,et al.  BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros , 2008, Nature.

[43]  R. Lu,et al.  Interferon regulatory factors 4 and 8 induce the expression of Ikaros and Aiolos to down-regulate pre-B-cell receptor and promote cell-cycle withdrawal in pre-B-cell development. , 2008, Blood.

[44]  S. Smale,et al.  Predominant Interaction of Both Ikaros and Helios with the NuRD Complex in Immature Thymocytes* , 2007, Journal of Biological Chemistry.

[45]  L. Chin,et al.  Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers , 2007, Nature.

[46]  Christopher B. Miller,et al.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.

[47]  A. Fisher,et al.  Ikaros DNA-binding proteins as integral components of B cell developmental-stage-specific regulatory circuits. , 2007, Immunity.

[48]  G. Trinchieri,et al.  Ikaros is required for plasmacytoid dendritic cell differentiation. , 2006, Blood.

[49]  L. Hennighausen,et al.  Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. , 2006, Blood.

[50]  H. Jumaa,et al.  BCR–ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells , 2006, Oncogene.

[51]  P. Kastner,et al.  Notch Activation Is an Early and Critical Event during T-Cell Leukemogenesis in Ikaros-Deficient Mice , 2006, Molecular and Cellular Biology.

[52]  N. Heerema,et al.  Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children's Cancer Group , 2004, Leukemia.

[53]  H. Kempski,et al.  Overexpression of the Ikaros  6 isoform is restricted to t(4;11) acute lymphoblastic leukaemia in children and infants and has a role in B‐cell survival , 2004, British journal of haematology.

[54]  A. Perkins,et al.  Widespread failure of hematolymphoid differentiation caused by a recessive niche-filling allele of the Ikaros transcription factor. , 2003, Immunity.

[55]  T. Kyo,et al.  Non-DNA-binding Ikaros isoform gene expressed in adult B-precursor acute lymphoblastic leukemia , 2002, Leukemia.

[56]  Philippe Kastner,et al.  Ikaros is critical for B cell differentiation and function , 2002, European journal of immunology.

[57]  A. Bank,et al.  Multiple hematopoietic defects and delayed globin switching in Ikaros null mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[58]  N. Dillon,et al.  Binding of Ikaros to the λ5 promoter silences transcription through a mechanism that does not require heterochromatin formation , 2001, The EMBO journal.

[59]  K. Takenaka,et al.  Dominant negative isoform of the Ikaros gene in patients with adult B-cell acute lymphoblastic leukemia. , 2000, Cancer research.

[60]  S. Neben,et al.  Defects in Hemopoietic Stem Cell Activity in Ikaros Mutant Mice , 1999, The Journal of experimental medicine.

[61]  Li Wu,et al.  Pre–T Cell Receptor (Tcr) and Tcr-Controlled Checkpoints in T Cell Differentiation Are Set by Ikaros , 1999, The Journal of experimental medicine.

[62]  T. Kyo,et al.  Decreases in Ikaros activity correlate with blast crisis in patients with chronic myelogenous leukemia. , 1999, Cancer research.

[63]  R. Kingston,et al.  Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes. , 1999, Immunity.

[64]  K. Georgopoulos,et al.  Cell-autonomous defects in dendritic cell populations of Ikaros mutant mice point to a developmental relationship with the lymphoid lineage. , 1997, Immunity.

[65]  A. Sharpe,et al.  Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. , 1996, Immunity.

[66]  K. Georgopoulos,et al.  A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma , 1995, Cell.

[67]  K. Georgopoulos,et al.  The Ikaros gene encodes a family of functionally diverse zinc finger DNA-binding proteins , 1994, Molecular and cellular biology.

[68]  A. Sharpe,et al.  The ikaros gene is required for the development of all lymphoid lineages , 1994, Cell.

[69]  D. Moore,et al.  Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitment. , 1992, Science.

[70]  S. Smale,et al.  LyF-1, a transcriptional regulator that interacts with a novel class of promoters for lymphocyte-specific genes , 1991, Molecular and cellular biology.

[71]  S. Granjeaud,et al.  Overexpression of dominant-negative Ikaros 6 protein is restricted to a subset of B common adult acute lymphoblastic leukemias that express high levels of the CD34 antigen. , 2003, The hematology journal : the official journal of the European Haematology Association.